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Recently, the association between nine variants of prothrom-
botic genes, previously associated with myocardial infarction,
were investigated in a large case–control study among young
individuals [1]. The focus on the young stems from the
assumption that atherosclerosis may play aminor role and that
any risk related to a genetic predisposition for a prothrombotic
state may be more easily detected. The study followed several
reports on the effects of factor (F)V Leiden and prothrombin
20210A in young women [2,3]. The study included 1210
patients with myocardial infarction before age 50 and 1210
controls. Overall, there was no evidence supporting an
association between these gene variants and the occurrence of
myocardial infarction. However, even in these young individ-
uals the presence of cardiovascular risk factors may have
inﬂuenced the results. In young individuals who smoke or have
hyperlipidemia, atheromatous plaque formation predisposes to
myocardial infarction. The aim of the present study was to take
the original reasoning even further by the most extreme
inclusion criteria, and investigate whether in young indi-
viduals amongst whom atherosclerosis is least likely, i.e. in
non-smoking, non-obese, non-hypertensive, non-hypercholes-
terolemic and non-diabetic persons, there would still be no
association between prothrombotic gene variants and the
development of myocardial infarction. Additionally, we evalu-
ated the inﬂuence of a positive family history on developing
myocardial infarction.
In the present study data from the same Atherosclerosis,
Thrombosis and Vascular Biology Italian Study Group were
used [1]. We selected individuals without major cardiovascu-
lar risk factors, including smoking, obesity [deﬁned as a body
mass index (BMI) >30.0 kg m)2], hypertension, hyper-
cholesterolemia and diabetes, resulting in 54 cases and
55 controls. Information on cardiovascular risk factors and
family history was collected by standardized questionnaires.
To decrease statistical variation, we also contrasted the
54 cases with all 1210 controls, under the assumption that in
non-diseased individuals the frequency of prothrombotic gene
variants will not differ between those with and without
cardiovascular risk factors. All participants provided a blood
sample for DNA isolation. Subsequently, the following
polymorphisms of genes encoding proteins involved in blood
coagulation, platelet function, ﬁbrinolysis and homocysteine
metabolism were analyzed: the G455A polymorphism in
the ﬁbrinogen gene, the G1691A polymorphism in the FV
gene (FV Leiden), the G20210A polymorphism in the
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prothrombin (factor II) gene, the G1097A polymorphism in
the factor VII gene, the C807T polymorphism in the
glycoprotein Ia gene, the C1565T polymorphism in the
glycoprotein IIIa gene, the G185T polymorphism of the A
subunit factor XIII gene, the 4G/5G polymorphism in the
plasminogen activator inhibitor type 1 gene and the C677T
polymorphism in the methylenetetrahydrofolate reductase
(MTHFR) gene. The association of each of these genetic
variants with risk was expressed as an odds ratio (OR) for
developing myocardial infarction with a corresponding 95%
conﬁdence interval (CI). Adjustments were made for sex, age
and geographic origin using unconditional logistic regression.
The 54 cases consisted of 38 men and 16 women, whereas
the control group was composed of 38 men and 17 women.
The mean age among cases was 35.6 years (range 20–47),
and 38.1 (range 22–45) in the controls. Mean BMI among
cases and control subjects was 24.5 kg m)2 and 23.6 kg m)2,
respectively. Despite our inclusion of patients without any
cardiovascular risk factor, we failed to ﬁnd evidence for an
excess risk of myocardial infarction for any of the nine
polymorphisms (Table 1). In contrast to the ﬁndings in other
reports [4,5], there was no association of the selected
polymorphisms with myocardial infarction, neither when
compared with the control group without cardiovascular risk
factors (N ¼ 55), nor when compared with the overall
control group (N ¼ 1210). As the allele frequencies in both
control groups were very similar, the choice of controls did
not materially change the odds ratios. In the controls, allele
frequencies of all polymorphisms were similar to those
reported in literature among Caucasians [6], except for the
MTHFR gene polymorphism, the frequency of which is
higher in the Italian population [7].
Table 1 The eﬀect of polymorphisms in prothrombotic genes in the young without cardiovascular risk factors and the inﬂuence of family history on
the risk of developing myocardial infarction
Polymorphism
Cases (N ¼ 54),
N (%)
Controls (N ¼ 55),
N (%)
OR*
(95% CI)
Controls (N ¼ 1210),
N (%)
OR
(95% CI)
G455A ﬁbrinogen gene
GG 38 (70.4) 34 (61.8) 744 (61.5)
GA 14 (25.9) 20 (36.4) 0.7 (0.3, 1.7) 398 (32.9) 0.7 (0.4, 1.3)
AA 2 (3.7) 1 (1.8) 0.9 (0.1, 11.9) 68 (5.6) 0.6 (0.1, 2.6)
G1691A factor V gene
GG 51 (94.4) 53 (96.4) 1166 (96.4)
GA 3 (5.6) 2 (3.6) 1.6 (0.2, 11.0) 44 (3.6) 1.6 (0.5, 5.2)
AA 0 0 – 0 –
G20210A prothrombin gene
GG 52 (96.3) 52 (94.5) 1171 (96.8)
GA 2 (3.7) 3 (5.5) 0.7 (0.1, 4.8) 38 (3.1) 1.2 (0.3, 5.1)
AA 0 0 – 1 (0.1) –
G1097A factor VII gene
GG 37 (68.5) 40 (72.7) 863 (71.3)
GA 17 (31.5) 14 (25.5) 1.1 (0.5, 2.6) 325 (26.9) 1.2 (0.7, 2.2)
AA 0 1 (1.8) – 22 (1.8) –
C807T platelet glycoprotein Ia gene
CC 25 (46.3) 24 (43.6) 483 (39.9)
CT 21 (38.9) 26 (47.3) 0.8 (0.3, 1.7) 557 (46.0) 0.7 (0.4, 1.3)
TT 8 (14.8) 5 (9.1) 1.3 (0.4, 4.9) 171 (14.1) 0.9 (0.4, 2.1)
C1565T platelet glycoprotein IIIa gene
CC 35 (64.8) 41 (74.5) 865 (71.5)
CT 16 (29.6) 12 (21.8) 1.7 (0.7, 4.3) 307 (25.4) 1.3 (0.7, 2.4)
TT 3 (5.6) 2 (3.6) 1.7 (0.2, 11.5) 38 (3.1) 2.0 (0.6, 7.1)
G185T factor XIII gene
GG 39 (72.2) 34 (61.8) 789 (65.2)
GT 13 (24.1) 18 (32.7) 0.6 (0.3, 1.5) 363 (30.0) 0.7 (0.4, 1.4)
TT 2 (3.7) 3 (5.5) 0.7 (0.1, 4.3) 58 (4.8) 0.7 (0.2, 3.2)
4G/5G PAI-1 gene
5G/5G 20 (37.0) 19 (34.5) 342 (28.3)
4G/5G 19 (35.2) 29 (52.7) 0.7 (0.3, 1.7) 588 (48.6) 0.6 (0.3, 1.1)
4G/4G 15 (27.8) 7 (12.7) 2.1 (0.7, 6.5) 280 (23.1) 0.9 (0.5, 1.8)
C677T MTHFR gene
CC 14 (25.9) 17 (30.9) 363 (30.0)
CT 24 (44.4) 28 (50.9) 1.0 (0.4, 2.8) 620 (51.2) 1.0 (0.5, 2.0)
TT 16 (29.6) 10 (18.2) 2.0 (0.7, 5.9) 252 (20.8) 1.7 (0.9, 3.2)
Family history of myocardial infarction
No 29 (53.7) 38 (69.1)
Yes 25 (46.3) 17 (30.9) 1.9 (0.9, 4.2)
*Odds ratio, adjusted for sex, age and geographical origin.
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This study included only survivors of myocardial infarction.
If prothrombotic mutations lead to severely altered plasma
concentrations of hemostatic factors, this may have produced
some early deaths and therefore an underestimation of the risk
of developing myocardial infarction. Because of the extreme
inclusion criteria we used, the study size has become too small
to enable us to exclude reliably an effect of variants with low
allele frequencies, such as FV Leiden and prothrombin 20210A
mutation, that have previously been found to increase risk in
young women [2,3]. Our results are therefore not inconsistent
with a mild deleterious effect of these variants. Family history
was a risk factor for myocardial infarction in young individuals
without a cardiovascular risk factor, as a higher prevalence of
familial myocardial infarction was found among cases (46.3%)
compared with controls without any cardiovascular risk factor
(30.9%), leading to an odds ratio of 1.9 (95% CI 0.9, 4.2).
Whether this increased risk is the result of socio-economic
circumstances and related lifestyle or an undiscovered genetic
inﬂuence is unclear. In conclusion, in a subgroup of young
survivors of myocardial infarction without any cardiovascular
risk factor, we found no support for a causal role of nine
prothrombotic genetic variants in the development of myo-
cardial infarction.
References
1 Atherosclerosis Thrombosis andVascular Biology Italian StudyGroup.
No evidence of association between prothrombotic gene polymor-
phisms and the development of acute myocardial infarction at a young
age. Circulation 2003; 107: 1117–22.
2 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM,
Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH.
Factor V Leiden (resistance to activated protein C) increases the risk of
myocardial infarction in young women. Blood 1997; 89: 2817–21.
3 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan
TE, Vos HL. A common prothrombin variant (20210 G to A) increases
the risk of myocardial infarction in young women. Blood 1997; 90:
1747–50.
4 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous
and arterial thrombotic disease. Blood 2000; 95: 1517–32.
5 Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and
arterial thrombotic disease. Thromb Haemost 2001; 85: 584–95.
6 Tang Z, Tracy RP. Candidate genes and conﬁrmed genetic polymor-
phisms associated with cardiovascular disease. J Thromb Thrombol
2001; 11: 49–81.
7 Margaglione M, D’Andrea G, d’AddeddaM, Giuliani N, Cappucci G,
Iannaccone L, Vecchione G, Grandone E, Brancaccio V, Di Minno G.
The methylenetetrahydrofolate reductase TT677 genotype is associated
with venous thrombosis independently of the coexistence of the FV
Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998;
79: 907–11.
Hemostatic effects of diets containing olive or soy oil in
hypertensive patients1
A. TR IF I LETT I , R . SCAMARDI , A . GAUDIO, A . LASCO and N . FR IS INA
Department of Internal Medicine, University of Messina, Messina, Italy
To cite this article: Trifiletti A, Scamardi R, Gaudio A, Lasco A, Frisina N. Hemostatic effects of diets containing olive or soy oil in hypertensive
patients. J Thromb Haemost 2005; 3: 179–80.
Various studies have shown that the Mediterranean diet is
associated with a low incidence of atherosclerotic disease [1–5].
A recent ﬁnding indicates that dietary interventions based on
the use of extra-virgin olive oil and a signiﬁcant reduction in
total and saturated fatty acids intake favorably aﬀect blood
pressure (BP) control in pharmacologically treated hyperten-
sive patients, signiﬁcantly decreasing the required daily dosage
of antihypertensives [6].
In the present study we evaluated the effect of extra-virgin
olive oil (MUFA) and soy oil (PUFA) diet for 3 months on the
hemostatic system, lipid proﬁle and blood pressure in a group
of hypertensive patients. This investigation was carried out in
44 consecutive patients [30 men and 14 women, mean age
49 ± 4 years, body mass index (BMI) 24.1 ± 3.0 kg m)2]
with essential hypertension with objective organic change
according to international guidelines [7], admitted to the
Division of Internal Medicine, University Polyclinic of
Messina, Italy. Patients taking oral anticoagulants, with
valvular heart disease, with severe heart failure or with any
other serious pathologywere excluded. Patients with symptoms
of peripheral vascular disease or ischemic heart disease were
also excluded. All patients were treated with antihypertensive
drugs (ACE inhibitors, b-blockers, diuretics, Ca2+ channel
blockers). Patients taking antiplatelets drugs (18/44) underwent
a 4-week washout of these drugs. The study protocol was
approved by the Ethics Committee of the University of
Messina School of Medicine. Patients were randomly divided
in two groups. These groups were prescribed twowell-balanced
diets with almost 6200 kJ daily, identical in daily content of
proteins (17 ± 3%), carbohydrates (56 ± 5%), total lipids
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